Edmond M. Kwan

2.9k total citations
62 papers, 622 citations indexed

About

Edmond M. Kwan is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Edmond M. Kwan has authored 62 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 35 papers in Cancer Research and 22 papers in Oncology. Recurrent topics in Edmond M. Kwan's work include Prostate Cancer Treatment and Research (48 papers), Cancer Genomics and Diagnostics (25 papers) and Radiopharmaceutical Chemistry and Applications (19 papers). Edmond M. Kwan is often cited by papers focused on Prostate Cancer Treatment and Research (48 papers), Cancer Genomics and Diagnostics (25 papers) and Radiopharmaceutical Chemistry and Applications (19 papers). Edmond M. Kwan collaborates with scholars based in Australia, Canada and United States. Edmond M. Kwan's co-authors include Arun Azad, Heidi Fettke, Alexander W. Wyatt, Manish Kohli, Lisa G. Horvath, Kate Mahon, Shidong Jia, Tiantian Zheng, Ben Tran and Pan Du and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Edmond M. Kwan

57 papers receiving 616 citations

Peers

Countries citing papers authored by Edmond M. Kwan

Since Specialization

Citations

This map shows the geographic impact of Edmond M. Kwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edmond M. Kwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edmond M. Kwan more than expected).

Fields of papers citing papers by Edmond M. Kwan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edmond M. Kwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edmond M. Kwan. The network helps show where Edmond M. Kwan may publish in the future.

Co-authorship network of co-authors of Edmond M. Kwan

This figure shows the co-authorship network connecting the top 25 collaborators of Edmond M. Kwan. A scholar is included among the top collaborators of Edmond M. Kwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edmond M. Kwan. Edmond M. Kwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of 20 Cycles of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer 2025 ·Journal of Nuclear Medicine ·(unknown), James P Buteau, (unknown), Edmond M. Kwan, Shahneen Sandhu, Arun Azad, Michael S. Hofman	1
2	Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [¹⁷⁷Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). 2024 ·Journal of Clinical Oncology ·Edmond M. Kwan, Michael S. Hofman, Sarah W.S. Ng, Louise Emmett, Shahneen Sandhu, James P Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Vijay Subhash, (unknown), Andrew M. Scott, Andrew Martin, Martin R. Stockler, (unknown), Matti Annala, Sofie H. Tolmeijer, Arun Azad, Ian D. Davis, Alexander W. Wyatt, (unknown)	5
3	Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer 2023 ·Clinical Cancer Research ·Sofie H. Tolmeijer, (unknown), Takayuki Sumiyoshi, Edmond M. Kwan, Sarah W.S. Ng, Matti Annala, (unknown), Cameron Herberts, (unknown), Paul Hamberg, Diederik M. Somford, Inge M. van Oort, Jack A. Schalken, Niven Mehra, Nielka P. van Erp, Alexander W. Wyatt	26
4	Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer 2023 ·JCO Clinical Cancer Informatics ·(unknown), Shandian Zhe, Hui‐Ming Lin, Arun Azad, Heidi Fettke, Edmond M. Kwan, Lisa G. Horvath, (unknown), Tiantian Zheng, (unknown), Shidong Jia, Robert M. Kirby, Manish Kohli	3
5	BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype 2023 ·EBioMedicine ·Heidi Fettke, Chao Dai, Edmond M. Kwan, Tiantian Zheng, Pan Du, Nicole Ng, Patricia Bukczynska, Maria Docanto, Louise Kostos, (unknown), Stephen Brown, (unknown), Kate Mahon, Lisa G. Horvath, Shidong Jia, Manish Kohli, Arun Azad	21
6	A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes 2023 ·npj Precision Oncology ·Elie Ritch, Cameron Herberts, Evan W. Warner, Sarah W.S. Ng, Edmond M. Kwan, Jack V. W. Bacon, Cecily Q. Bernales, Elena Schönlau, (unknown), Veda N. Giri, Corinne Maurice‐Dror, Gillian Vandekerkhove, Steven J.M. Jones, Kim N., Alexander W. Wyatt	6
7	Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer 2022 ·The Prostate ·Edmond M. Kwan, Alexander W. Wyatt	12
8	Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation 2022 ·Frontiers in Oncology ·Edmond M. Kwan, Alexander W. Wyatt, Kim N.	19
9	Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study 2021 ·European Journal of Cancer ·A. Antón, Shirley Wong, (unknown), Andrew Weickhardt, Arun Azad, Edmond M. Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey C. Goh, (unknown), Peter Gibbs, Ben Tran, (unknown)	8
10	Genomic landscape of older versus younger men with metastatic castration-resistant prostate cancer 2021 ·Asia-Pacific Journal of Clinical Oncology ·(unknown), (unknown), Christine Hauser, Patricia Bukczynska, Nicole Ng, (unknown), (unknown), Kate Mahon, Winston Tan, Tiantian Zheng, Jianjun Yu, Chao Dai, Pan Du, Shidong Jia, (unknown), Manish Kohli, Arun Azad, Edmond M. Kwan	1
11	579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC) 2021 ·Annals of Oncology ·Daniel P. Petrylak, José Luis Perez‐Gracia, Louis Lacombe, Diogo Assed Bastos, Hakim Mahammedi, Edmond M. Kwan, Stefanie Zschäbitz, Andrew J. Armstrong, Russell K. Pachynski, Jeffrey C. Goh, Mauricio Burotto, Gwénaëlle Gravis, Steve McCune, Juan Carlos Vázquez Limón, Margitta Retz, Fred Saad, Neha P. Amin, Jianqing Li, Keziban Ünsal-Kaçmaz, Karim Fizazi	11
12	Analytical Validation of an Error-Corrected Ultra-Sensitive Ctdna Next-Generation Sequencing Assay 2020 ·BioTechniques ·Heidi Fettke, Jason A. Steen, Edmond M. Kwan, Patricia Bukczynska, Shivakumar Keerthikumar, David L. Goode, Maria Docanto, Nicole Ng, Luciano G. Martelotto, Christine Hauser, Melissa C. Southey, Arun Azad, Tú Nguyen‐Dumont	5
13	Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer 2020 ·European Urology Focus ·Heidi Fettke, Edmond M. Kwan, Patricia Bukczynska, Nicole Ng, Tú Nguyen‐Dumont, Melissa C. Southey, Ian D. Davis, Andrew Mant, Phillip Parente, (unknown), Christine Hauser, Arun Azad	13
14	Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? 2020 ·European Urology Focus ·(unknown), Edmond M. Kwan, Ben Tran, Peter Gibbs, Johann S. de Bono, Maarten J. IJzerman	11
15	Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN) 2020 ·European Urology Oncology ·Megan Crumbaker, (unknown), Andrew O. Yam, Andrew Nguyen, Bao Ho, Lyn Chan, (unknown), (unknown), (unknown), Edmond M. Kwan, Arun Azad, Shikha Sharma, Trevor J. Pugh, Arnavaz Danesh, (unknown), Peter Eu, Anthony M. Joshua, Louise Emmett	31
16	Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer 2020 ·EBioMedicine ·Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, (unknown), (unknown), Pan Du, Shidong Jia, Siddhartha Yadav, Lisa G. Horvath, Kate Mahon, Edmond M. Kwan, Heidi Fettke, Jianjun Yu, Arun Azad	89
17	226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC) 2020 ·Annals of Oncology ·Allan Jensen, (unknown), (unknown), Jeremy Shapiro, Andrew Weickhardt, Lavinia Spain, Arun Azad, Edmond M. Kwan, (unknown), Javier Torres, Phillip Parente, Prudence A. Francis, Francis Parnis, Jeffrey C. Goh, Peter Gibbs, Ben Tran, A. Antón	1
18	Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer 2019 ·European Urology Focus ·Edmond M. Kwan, Heidi Fettke, Maria Docanto, Sarah Q. To, Patricia Bukczynska, Andrew Mant, David Pook, Nicole Ng, (unknown), Stefano Mangiola, Eva Segelov, Kate Mahon, Ian D. Davis, Phillip Parente, Carmel Pezaro, (unknown), Lisa G. Horvath, Arun Azad	11
19	Impact of access to novel therapies on the initial management of castrate‐resistant prostate cancer: an Australian multicentre study 2019 ·Internal Medicine Journal ·Edmond M. Kwan, (unknown), Alice R.T. Bergin, (unknown), (unknown), A. Antón, David Campbell, Shirley Wong, Mark Rosenthal, Peter Gibbs, Ben Tran	4
20	Plasma Cell-Free DNA (cfDNA) Concentration and Outcomes in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Patients Treated with Androgen Receptor Signalling Inhibitors (ARSIs) 2018 ·Asia-Pacific Journal of Clinical Oncology ·Heidi Fettke, Edmond M. Kwan, Andrew Mant, Maria Docanto, Patricia Bukczynska, Sarah Q. To, Mark Waltham, Nicole Ng, Phillip Parente, Carmel Pezaro, Arun Azad	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact